Phase II Study Opens Window For Sellas' NeuVax In Triple-Negative Breast Cancer
Executive Summary
Sellas is pursuing accelerated approval for NeuVax in triple-negative breast cancer based on Phase II data, but that may be a tough sell with the FDA.